Results 101 to 110 of about 8,510 (199)

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report

JTO Clinical and Research Reports
Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms.
Alexius John, MBBS, FRACP, Joanna Vick, BSc, NMP, Sarah Sarker, BSc, PGDip, Elizabeth Middleton, BN, Elizabeth Cartwright, MD, MRCP, Thubeena Manickavasagar, MD, MRCP, David McMahon, MB, BCh, BAO, MRCP, Nadza Tokaca, BMBCh, MRCP, Sanjay Popat, PhD, FRCP   +8 more
doaj   +1 more source

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

Frontiers in Public Health
BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients.
Wenjie Liu, Wenjie Liu, Wenjie Liu, Wenjie Liu, Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Peng Chen, Peng Chen, Peng Chen, Peng Chen   +11 more
doaj   +1 more source

Induction Regimens in High‐Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities

Cancer Medicine, Volume 14, Issue 22, November 2025.
ABSTRACT Background Numerous induction therapies have been evaluated for high‐risk neuroblastoma (HRNBL). It is not known how these regimens' response rates nor toxicities compare. We aimed to describe and compare key features of HRNBL induction regimens and their associations with study‐level end‐induction response (EIR).
Samantha D. Martin, Eva C. Robinson, Edie Weller, Rochelle Bagatell, Lucas Moreno, Steven G. DuBois   +5 more
wiley   +1 more source

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study

JTO Clinical and Research Reports
Introduction: Lorlatinib was found to have improved efficacy versus crizotinib in the global phase 3 CROWN study (NCT03052608). Similar results were revealed for the Japanese population as for the overall population. We present results from the unplanned
Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD   +10 more
doaj   +1 more source

Molecular Mechanisms and Treatment Strategies of ALK‐Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers

Thoracic Cancer, Volume 16, Issue 21, November 2025.
Inhibition of EML‐ALK function by TKI. In cells, not treated with TKI, ATP binding occurs in the active site (pocket) of the hybrid protein, leading to its activation and functional effects. Introduction of a TKI leads to TKI compete with ATP for binding to the active site.
Elena Klenova
wiley   +1 more source

ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models

iScience
Summary: Hepatocellular carcinoma (HCC) currently lacks effective therapies, leaving a critical need for new treatment options. A previous study identified the anaplastic lymphoma kinase (ALK) amplification in HCC patients, raising the question of ...
Suresh Bugide, Dhana Sekhar Reddy, Parmanand Malvi, Romi Gupta, Narendra Wajapeyee   +4 more
doaj   +1 more source

EML4‐ALK‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review

Clinical Case Reports
We report a case showing that lorlatinib is effective in treating EML4‐ALK‐positive low‐grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for ...
Qiongqian Li, Tongze Cai, Xiaoming Zheng, Shunrong Zhang, Chanjuan Li, Huang Tang, Zhiyong Yu, Jianlong Zhou   +7 more
semanticscholar   +1 more source

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report

Cancer Management and Research, 2022
Dan Li, Jiayin Liu, Xue Zhang, Jing Han, Hui Jin, Long Wang, Li Feng, Zhisong Fan, Jing Zuo, Yudong Wang Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, People’s Republic ...
Li D, Liu J, Zhang X, Han J, Jin H, Wang L, Feng L, Fan Z, Zuo J, Wang Y   +9 more
doaj  

New generation anaplastic lymphoma kinase inhibitors [PDF]

, 2019
Anaplastic lymphoma kinase (ALK) gene translocations are pro-tumoral driver alterations that encompass 3*7% of non-squamous non-small cell lung cancer (NSCLC) with specific, clinic and histologic features.
Bronte G., Burgio M. A., Cravero P., Crino L., Delmonte A., Martinelli G., Ulivi P., Verlicchi A.   +7 more
core   +1 more source

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry

Journal of Analytical Methods in Chemistry, 2019
In the present study, we developed and validated a rapid and simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of lorlatinib in mouse serum and tissue samples, and such a method was successfully applied to ...
Wei Chen, Yafei Shi, Shuya Qi, Haiyan Zhou, Chunyu Li, Dujia Jin, Guohui Li   +6 more
doaj   +1 more source